CLYM

Climb Bio is a pre-revenue, clinical-stage immunology biotech whose entire value rests on two early-stage candidates — budoprutug and CLYM116 — neither of which has generated a dollar of product revenue. FY2025 net loss was -$59.9M on zero revenue, R&D spend exploded +225.8% YoY to $46.7M as programs advanced, and operating cash flow swung to -$54.4M (from a small positive in FY2024, hence the -249.3% YoY). This is a binary, science-driven story, not a fundamentals story.

The balance sheet is the immediate problem. Cash & equivalents fell 59.1% YoY to just $35.7M, and total assets dropped 22.8% to $168M as the company consumed its IPO/Private-Placement proceeds. Management's own MD&A states cash, equivalents and marketable securities will fund operations 'into 2028' — that runway claim only holds because marketable securities sit outside the $35.7M cash line, but at a $54M/yr burn the company will almost certainly need to raise. The 10-K is explicit: 'we may finance our operations through equity offerings… Adequate funding may not be available… on terms acceptable to us, or at all.' Translation: expect dilution. Shares outstanding already dropped 29.2% YoY (post reverse-split / restructuring optics), and the -$290M accumulated deficit shows the long history of shareholder value destruction.